undamentalytics Newsletter

Nissenson Allen: insider trades

Officer, Director at 2 companies we cover. 1 open-market purchase and 12 sales not made under a pre-set plan, reported from March 16, 2010 to May 23, 2022.

Would copying Nissenson Allen’s purchases have beaten the S&P 500?

Too few purchases to judge. None of their purchases has 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. After their sales, the shares moved −0.2% against the index over 12 months on average (a negative figure means selling was the right call); 58% trailed it. None of their purchases could be priced, so there is no copy portfolio.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Nissenson Allen: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 12 +2.0% +0.8% 42% 5 0.96 0.39 No reliable evidence
Sales, 12 months after the report 12 −0.2% −3.0% 58% 5 −0.42 0.69 No reliable evidence
Sales, 12 months after the trade 12 −0.8% −4.8% 58% 5 −0.64 0.56 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
DaVita DVA Chief Medical Officer012March 16, 2010February 18, 2014
Elicio Therapeutics, Inc. ELTX —10May 23, 2022May 23, 2022

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
May 23, 2022May 19, 2022 ELTX Purchase $10,925 not yetnot yetnot yet
February 18, 2014February 13, 2014 DVA Sale $168,510 −0.7%−6.1%−6.5%
December 18, 2013December 17, 2013 DVA Sale $175,242 +7.8%+6.5%+8.3%
May 15, 2013May 13, 2013 DVA Sale $101,167 −12.7%−10.6%−14.0%
March 8, 2013March 6, 2013 DVA Sale $299,778 +1.7%−6.4%−11.5%
November 16, 2012November 15, 2012 DVA Sale $462,375 −7.5%−29.2%−31.3%
August 8, 2012August 6, 2012 DVA Sale $387,626 +18.0%−4.2%−5.6%
May 25, 2012May 23, 2012 DVA Sale $481,280 +11.4%+25.1%+30.1%
May 19, 2011May 17, 2011 DVA Sale $216,806 −3.4%−1.8%−5.6%
March 1, 2011February 25, 2011 DVA Sale $86,586 +3.1%+0.5%+3.9%
November 12, 2010November 9, 2010 DVA Sale $131,778 −1.6%−4.1%−4.0%
June 21, 2010June 17, 2010 DVA Sale $12,648 0.0%+12.7%+10.7%
March 16, 2010March 12, 2010 DVA Sale $262,688 +7.8%+15.3%+15.6%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Nissenson Allen traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.